Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug delivery technology, announced that Serina Therapeutics ...

In September 2007, the EMEA organized a workshop on immunogenicity assessment, giving various stakeholders the opportunity to comment and critically discuss the European draft guideline 3.

Immunogenicity was assessed by hemagglutination-inhibition (HI) prevaccination and 28 days after each vaccination. Immunogenic non-inferiority QIV versus TIV for shared strains, and superiority ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

So, what is the adjuvant element that stimulates immunogenicity and makes these vaccines successful? Ishii and colleagues now reveal that TBK1 (TANK-binding kinase 1) mediates the adjuvant effect ...

Novavax (NVAX) announced that the first participants have been dosed in its COVID-19-Influenza Combination and stand-alone seasonal influenza ...

The concomitant administration of multiple vaccines at a single clinic visit reduces the number of required visits to healthcare providers and can improve compliance with vaccine recommendations ...

Enhance Toxicity Assessments with Human-Relevant Data Discover how advanced ex vivo human skin models are reshaping toxicity ...

The study aims to assess the vaccine's tolerability, immunogenicity, and safety in preventing invasive pneumococcal disease.